Aptar reports second quarter 2022 results
Crystal lake, ill.--(business wire)--aptargroup, inc. (nyse:atr), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, today reported net income of $64 million for the quarter ended june 30, 2022, a 15% increase over the prior year. reported sales grew 4% and core sales increased by 10% over the prior year. “aptar delivered a strong quarter, remaining resilient while navigating a very dynamic and uncertain environment. as we look to the year ahead, we will remain focused on pricing initiatives to help offset continued rising input costs, managing our expenses and prudently allocating our capital by investing in services and product lines that drive shareholder return over the long term,” said stephan b. tanda, president and ceo, aptar. second quarter 2022 summary reported sales grew 4% and net income increased 15% to $64 million core sales increased 10% and adjusted ebitda increased 8% to $160 million reported earnings per share increased 17% to $0.95 compared to $0.81 in the prior year adjusted earnings per share increased 13% to $0.96 compared to $0.85 in the prior year (including comparable exchange rates) each segment achieved sales growth through improved volume as well as increased pricing, with pharma and beauty + home segments reaching double-digit core sales growth second quarter results for the quarter ended june 30, 2022, reported sales increased 4% to $845 million compared to $811 million in the prior year. core sales, excluding the impact from changes in currency exchange rates and acquisitions, increased 10%. second quarter segment sales analysis (change over prior year) pharma beauty + home food + beverage total aptargroup core sales growth 12% 10% 8% 10% acquisitions 1% 0% 0% 0% currency effects (1) (8%) (7%) (2%) (6%) total reported sales growth 5% 3% 6% 4% (1) - currency effects are approximated by translating last year's amounts at this year's foreign exchange rates. aptar’s pharma segment achieved double-digit core sales growth due to increased volumes across each end market. demand for nasal devices for allergic rhinitis treatments, emergency medicines and decongestants principally drove the growth in the prescription drug and consumer health care markets. sales of aptar’s elastomer components for injected medicines remained strong across multiple uses, including biologics. aptar’s beauty + home segment grew through pricing initiatives as well as increased volume in the beauty and personal care markets. several categories previously under pressure due to the pandemic showed recovery during the quarter, including fragrance, facial skincare, haircare and sunscreens. growth in aptar’s food + beverage segment was driven primarily by pricing, with volumes in the food market softening, especially in north america, after a period of strong growth. volumes in the beverage market increased as demand recovered in the quarter. aptar reported second quarter earnings per share of $0.95, an increase of 17%, compared to $0.81 during the same period a year ago. second quarter adjusted earnings per share, excluding restructuring charges, acquisition costs and the unrealized loss on an equity investment, were $0.96, an increase of 13%, compared to $0.85 in the prior year, including comparable exchange rates. the prior year’s adjusted earnings included an effective tax rate of 25% (approximately $0.04 cents per share impact compared to the current period effective tax rate of 29%). year-to-date results for the six months ended june 30, 2022, reported sales increased 6% to $1.69 billion compared to $1.59 billion in the prior year. core sales, excluding the impact from changes in currency exchange rates and acquisitions, increased 11%. six months year-to-date segment sales analysis (change over prior year) pharma beauty + home food + beverage total aptargroup core sales growth 13% 10% 13% 11% acquisitions 1% 0% 0% 0% currency effects (1) (7)% (5)% (2)% (5)% total reported sales growth 7% 5% 11% 6% (1) - currency effects are approximated by translating last year's amounts at this year's foreign exchange rates. for the six months ended june 30, 2022, aptar’s reported earnings per share were $1.88, a decrease of 8%, compared to $2.05 reported a year ago. current year adjusted earnings per share, excluding restructuring charges, acquisition costs and the unrealized gains or losses on an equity investment, were $1.92 and increased 2% from prior year adjusted earnings per share of $1.89, including comparable exchange rates. the prior year’s adjusted earnings included an effective tax rate of 20% (approximately $0.19 cents per share impact compared to current period effective tax rate of 28%). outlook regarding aptar’s third quarter outlook, tanda stated, “we are recovering nicely in the critical markets that had previously been impacted by the pandemic, including our pharma segment’s prescription drug and consumer health care markets which are expected to continue strong momentum in the coming quarter. at the same time, we are operating in an uncertain environment, which continues to be affected by rising inflation, the ongoing war in ukraine, supply chain disruptions, and a very tight u.s. labor market. in addition, the stronger dollar is expected to continue to have an impact on our results. we believe we are well positioned to navigate a potential economic downturn due to the strength of our balance sheet, our disciplined approach to capital management and our broad portfolio of innovative solutions that serve multiple essential markets.” aptar expects earnings per share for the third quarter of 2022, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $0.90 to $1.00. this guidance is based on an effective tax rate range of 28% to 30% which compares to an effective tax rate of 28% on prior year adjusted earnings. the midpoint of this guidance range represents a 10% increase over the prior year third quarter adjusted earnings per share when currency translation effects are equalized. the earnings per share guidance range was based on a euro/us$ exchange rate of 1.02 and the spot rates at the end of june for all other currencies. our currency exchange rate assumptions equate to an approximately $0.08 per share headwind when compared to the prior year third quarter earnings. cash dividends and share repurchases as previously announced, aptar’s board of directors declared a quarterly cash dividend of $0.38 per share. the payment date is august 17, 2022, to stockholders of record as of july 27, 2022. during the second quarter, aptar repurchased 348 thousand shares for approximately $37 million, leaving $147 million authorized for common stock repurchases at the end of the second quarter. aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. open conference call there will be a conference call held on friday, july 29, 2022 at 8:00 a.m. central time to discuss the company’s second quarter results for 2022. the call will last approximately one hour. interested parties are invited to listen to a live webcast by visiting the investor relations page at www.aptar.com. replay of the conference call can also be accessed for a limited time on the investor relations page of the website. about aptar aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services. aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home care, food and beverage. using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. aptar is headquartered in crystal lake, illinois and has 13,000 dedicated employees in 20 countries. for more information, visit www.aptar.com. presentation of non-gaap information this press release refers to certain non-gaap financial measures, including current year adjusted earnings per share and adjusted ebitda, which exclude the impact of business transformation charges (restructuring initiatives), acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities. core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. non-gaap financial measures may not be comparable to similarly titled non-gaap financial measures provided by other companies. aptar’s management believes these non-gaap financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect aptar’s core operating performance. these non-gaap financial measures also provide investors with certain information used by aptar’s management when making financial and operational decisions. free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. we use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. we believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. these non-gaap financial measures should not be considered in isolation or as a substitute for gaap financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. a reconciliation of non-gaap financial measures to the most directly comparable gaap measures is included in the accompanying tables. our outlook is provided on a non-gaap basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the company's routine activities, such as restructuring and acquisition costs. this press release contains forward-looking statements, including certain statements set forth under the “outlook” section of this press release. words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. forward-looking statements are made pursuant to the safe harbor provisions of section 27a of the securities act of 1933 and section 21e of the securities exchange act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide including the invasion of ukraine by the russian military and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising energy costs and certain supply chain disruptions; the impact of covid-19 and its variants on our global supply chain and our global customers, employees and operations, which has elevated and will continue to elevate many of the risks and uncertainties discussed below; economic conditions worldwide, including inflationary conditions in the u.s. and potential deflationary or inflationary conditions in other regions we rely on for growth; the availability of direct labor workers and the increase in direct labor costs, especially in north america; our ability to preserve organizational culture and maintain employee productivity in the work-from-home environment caused by the current pandemic; the availability of raw materials and components (particularly from sole sourced suppliers) as well as the financial viability of these suppliers; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs (particularly resin, metal, anodization costs and energy costs); significant fluctuations in foreign currency exchange rates or our effective tax rate; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key accounts; our ability to successfully implement facility expansions and new facility projects; our ability to offset inflationary impacts with cost containment, productivity initiatives or price increases; changes in capital availability or cost, including interest rate fluctuations; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired, including contingent consideration valuation; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; cybersecurity threats that could impact our networks and reporting systems; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes or difficulties in complying with government regulation; changing regulations or market conditions regarding environmental sustainability; work stoppages due to labor disputes; competition, including technological advances; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations.. for additional information on these and other risks and uncertainties, please see our filings with the securities and exchange commission, including the discussion under “risk factors” and “management’s discussion and analysis of financial condition and results of operations” in our form 10-k and form 10-qs. we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. aptargroup, inc. condensed consolidated financial statements (unaudited) (in thousands, except per share data) consolidated statements of income three months ended june 30, six months ended june 30, 2022 2021 2022 2021 net sales $ 844,543 $ 811,032 $ 1,689,475 $ 1,587,786 cost of sales (exclusive of depreciation and amortization shown below) 549,010 523,050 1,091,738 1,011,755 selling, research & development and administrative 135,382 140,913 280,923 275,261 depreciation and amortization 58,552 57,790 117,217 115,228 restructuring initiatives 428 4,876 719 8,548 operating income 101,171 84,403 198,878 176,994 other income (expense): interest expense (11,982 ) (7,175 ) (20,912 ) (14,590 ) interest income 989 624 1,277 1,005 net investment (loss) gain (483 ) (1,611 ) (1,733 ) 15,198 equity in results of affiliates (276 ) 81 (362 ) (434 ) miscellaneous, net 52 (2,028 ) (1,051 ) (2,991 ) income before income taxes 89,471 74,294 176,097 175,182 provision for income taxes 25,858 19,020 50,113 35,969 net income $ 63,613 $ 55,274 $ 125,984 $ 139,213 net loss attributable to noncontrolling interests 12 2 64 15 net income attributable to aptargroup, inc. $ 63,625 $ 55,276 $ 126,048 $ 139,228 net income attributable to aptargroup, inc. per common share: basic $ 0.97 $ 0.84 $ 1.92 $ 2.12 diluted $ 0.95 $ 0.81 $ 1.88 $ 2.05 average numbers of shares outstanding: basic 65,475 65,818 65,509 65,525 diluted 66,900 68,086 66,969 67,869 aptargroup, inc. condensed consolidated financial statements (unaudited) (continued) ($ in thousands) consolidated balance sheets june 30, 2022 december 31, 2021 assets cash and equivalents $ 240,474 $ 122,925 short-term investments — 740 total cash and equivalents, and short-term investments 240,474 123,665 accounts and notes receivable, net 703,000 671,350 inventories 470,600 441,464 prepaid and other current assets 144,567 121,729 total current assets 1,558,641 1,358,208 property, plant and equipment, net 1,256,992 1,275,877 goodwill 936,107 974,157 other assets 506,370 533,122 total assets $ 4,258,110 $ 4,141,364 liabilities and equity short-term obligations $ 70,286 $ 289,627 accounts payable, accrued and other liabilities 751,746 692,865 total current liabilities 822,032 982,492 long-term obligations 1,271,752 907,024 deferred liabilities and other 215,862 267,248 total liabilities 2,309,646 2,156,764 aptargroup, inc. stockholders' equity 1,934,111 1,969,407 noncontrolling interests in subsidiaries 14,353 15,193 total equity 1,948,464 1,984,600 total liabilities and equity $ 4,258,110 $ 4,141,364 aptargroup, inc. reconciliation of adjusted ebit and adjusted ebitda to net income (unaudited) ($ in thousands) three months ended june 30, 2022 consolidated pharma beauty + home food + beverage corporate & other net interest net sales $ 844,543 $ 340,231 $ 371,346 $ 132,966 $ — $ — reported net income $ 63,613 reported income taxes 25,858 reported income before income taxes 89,471 87,445 21,053 7,594 (15,628 ) (10,993 ) adjustments: restructuring initiatives 428 — 420 8 — net unrealized investment loss 483 — — — 483 adjusted earnings before income taxes 90,382 87,445 21,473 7,602 (15,145 ) (10,993 ) interest expense 11,982 11,982 interest income (989 ) (989 ) adjusted earnings before net interest and taxes (adjusted ebit) 101,375 87,445 21,473 7,602 (15,145 ) — depreciation and amortization 58,552 23,561 23,406 10,103 1,482 adjusted earnings before net interest, taxes, depreciation and amortization (adjusted ebitda) $ 159,927 $ 111,006 $ 44,879 $ 17,705 $ (13,663 ) $ — adjusted ebitda margins (adjusted ebitda / reported net sales) 18.9 % 32.6 % 12.1 % 13.3 % three months ended june 30, 2021 consolidated pharma beauty + home food + beverage corporate & other net interest net sales $ 811,032 $ 325,343 $ 360,246 $ 125,443 $ — $ — reported net income $ 55,274 reported income taxes 19,020 reported income before income taxes 74,294 81,806 12,122 9,691 (22,774 ) (6,551 ) adjustments: restructuring initiatives 4,876 38 1,457 117 3,264 net unrealized investment loss 1,611 — — — 1,611 transaction costs related to acquisitions 2,434 2,434 — — — adjusted earnings before income taxes 83,215 84,278 13,579 9,808 (17,899 ) (6,551 ) interest expense 7,175 7,175 interest income (624 ) (624 ) adjusted earnings before net interest and taxes (adjusted ebit) 89,766 84,278 13,579 9,808 (17,899 ) — depreciation and amortization 57,790 21,701 24,331 9,818 1,940 adjusted earnings before net interest, taxes, depreciation and amortization (adjusted ebitda) $ 147,556 $ 105,979 $ 37,910 $ 19,626 $ (15,959 ) $ — adjusted ebitda margins (adjusted ebitda / reported net sales) 18.2 % 32.6 % 10.5 % 15.6 % aptargroup, inc. reconciliation of adjusted ebit and adjusted ebitda to net income (unaudited) ($ in thousands) six months ended june 30, 2022 consolidated pharma beauty + home food + beverage corporate & other net interest net sales $ 1,689,475 $ 682,693 $ 739,545 $ 267,237 $ — $ — reported net income $ 125,984 reported income taxes 50,113 reported income before income taxes 176,097 179,651 36,734 16,567 (37,220 ) (19,635 ) adjustments: restructuring initiatives 719 — 678 41 — net unrealized investment loss 2,574 — — — 2,574 adjusted earnings before income taxes 179,390 179,651 37,412 16,608 (34,646 ) (19,635 ) interest expense 20,912 20,912 interest income (1,277 ) (1,277 ) adjusted earnings before net interest and taxes (adjusted ebit) 199,025 179,651 37,412 16,608 (34,646 ) — depreciation and amortization 117,217 46,907 46,965 20,332 3,013 adjusted earnings before net interest, taxes, depreciation and amortization (adjusted ebitda) $ 316,242 $ 226,558 $ 84,377 $ 36,940 $ (31,633 ) $ — adjusted ebitda margins (adjusted ebitda / reported net sales) 18.7 % 33.2 % 11.4 % 13.8 % six months ended june 30, 2021 consolidated pharma beauty + home food + beverage corporate & other net interest net sales $ 1,587,786 $ 639,175 $ 707,192 $ 241,419 $ — $ — reported net income $ 139,213 reported income taxes 35,969 reported income before income taxes 175,182 169,476 21,810 19,701 (22,220 ) (13,585 ) adjustments: restructuring initiatives 8,548 73 2,553 38 5,884 net unrealized investment gain (15,198 ) — — — (15,198 ) transaction costs related to acquisitions 2,434 2,434 — — — adjusted earnings before income taxes 170,966 171,983 24,363 19,739 (31,534 ) (13,585 ) interest expense 14,590 14,590 interest income (1,005 ) (1,005 ) adjusted earnings before net interest and taxes (adjusted ebit) 184,551 171,983 24,363 19,739 (31,534 ) — depreciation and amortization 115,228 42,480 48,903 19,877 3,968 — adjusted earnings before net interest, taxes, depreciation and amortization (adjusted ebitda) $ 299,779 $ 214,463 $ 73,266 $ 39,616 $ (27,566 ) $ — adjusted ebitda margins (adjusted ebitda / reported net sales) 18.9 % 33.6 % 10.4 % 16.4 % aptargroup, inc. reconciliation of adjusted earnings per diluted share (unaudited) (in thousands, except per share data) three months ended june 30, six months ended june 30, 2022 2021 2022 2021 income before income taxes $ 89,471 $ 74,294 $ 176,097 $ 175,182 adjustments: restructuring initiatives 428 4,876 719 8,548 net unrealized investment loss (gain) 483 1,611 2,574 (15,198 ) transaction costs related to acquisitions — 2,434 — 2,434 foreign currency effects (1) (5,983 ) (9,657 ) adjusted earnings before income taxes $ 90,382 $ 77,232 $ 179,390 $ 161,309 provision for income taxes $ 25,858 $ 19,020 $ 50,113 $ 35,969 adjustments: restructuring initiatives 111 1,144 188 1,985 net unrealized investment loss (gain) 119 370 631 (3,496 ) transaction costs related to acquisitions — 442 — 442 foreign currency effects (1) (1,532 ) (1,982 ) adjusted provision for income taxes $ 26,088 $ 19,444 $ 50,932 $ 32,918 net income attributable to noncontrolling interests $ 12 $ 2 $ 64 $ 15 net income attributable to aptargroup, inc. $ 63,625 $ 55,276 $ 126,048 $ 139,228 adjustments: restructuring initiatives 317 3,732 531 6,563 net unrealized investment loss (gain) 364 1,241 1,943 (11,702 ) transaction costs related to acquisitions — 1,992 — 1,992 foreign currency effects (1) (4,451 ) (7,675 ) adjusted net income attributable to aptargroup, inc. $ 64,306 $ 57,790 $ 128,522 $ 128,406 average number of diluted shares outstanding 66,900 68,086 66,969 67,869 net income attributable to aptargroup, inc. per diluted share $ 0.95 $ 0.81 $ 1.88 $ 2.05 adjustments: restructuring initiatives — 0.05 0.01 0.10 net unrealized investment loss (gain) 0.01 0.02 0.03 (0.17 ) transaction costs related to acquisitions — 0.03 — 0.03 foreign currency effects (1) (0.06 ) (0.12 ) adjusted net income attributable to aptargroup, inc. per diluted share $ 0.96 $ 0.85 $ 1.92 $ 1.89 (1) foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates. aptargroup, inc. reconciliation of free cash flow to net cash provided by operations (unaudited) (in thousands) three months ended june 30, six months ended june 30, 2022 2021 2022 2021 net cash provided by operations $ 84,577 $ 103,396 $ 176,654 $ 175,581 capital expenditures (74,204 ) (73,155 ) (147,262 ) (137,039 ) proceeds from government grants 4,839 — 12,794 — free cash flow $ 15,212 $ 30,241 $ 42,186 $ 38,542 aptargroup, inc. reconciliation of adjusted earnings per diluted share (unaudited) (in thousands, except per share data) three months ending september 30, expected 2022 2021 income before income taxes $ 66,234 adjustments: restructuring initiatives 10,223 net unrealized investment loss 9,021 transaction costs related to acquisitions 1,793 foreign currency effects (1) (7,385 ) adjusted earnings before income taxes $ 79,886 provision for income taxes $ 19,340 adjustments: restructuring initiatives 2,351 net unrealized investment loss 2,075 transaction costs related to acquisitions 447 foreign currency effects (1) (2,156 ) adjusted provision for income taxes $ 22,057 net income attributable to noncontrolling interests $ 366 net income attributable to aptargroup, inc. $ 47,260 adjustments: restructuring initiatives 7,872 net unrealized investment loss 6,946 transaction costs related to acquisitions 1,346 foreign currency effects (1) (5,229 ) adjusted net income attributable to aptargroup, inc. $ 58,195 average number of diluted shares outstanding 67,801 net income attributable to aptargroup, inc. per diluted share (2) $ 0.70 adjustments: restructuring initiatives 0.12 net unrealized investment loss 0.10 transaction costs related to acquisitions 0.02 foreign currency effects (1) (0.08 ) adjusted net income attributable to aptargroup, inc. per diluted share (2) $0.90 - $1.00 $ 0.86 (1) foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using a euro/us$ exchange rate of 1.02 and the spot rates as of june 30, 2022 for all other applicable foreign currency exchange rates. (2) aptargroup’s expected earnings per share range for the third quarter of 2022, excluding any restructuring expenses, acquisition costs and changes in fair value of equity investments, is based on an effective tax rate range of 28% to 30%. this tax rate range compares to our third quarter of 2021 effective tax rate of 29% on reported and 28% on adjusted earnings per share.
